Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
The former Microsoft CEO launched "Just the Facts" with USAFacts to provide clear, factual information on key issues, like health, the economy, and immigration.
Research Director at CFRA Research, Ken Leon, joins Cheddar to discuss Disney's earnings plus the shake up happening at Warner Brothers Discovery. Watch!
OpenTable CEO joins Cheddar to discuss this summer's top restaurant trends, how best to make a reservation and what perks you can now get on the app. Watch!
Nancy Clark, President of Verizon Value, on Total Wireless’s rebranding and its commitment to top speeds, network quality, and value for prepaid customers.
